Veru announced submission of an Investigational New Drug application with the U.S. Food and Drug Administration for the development of enobosarm for obesity. Glucagon-like peptide-1 receptor agonist drugs are very effective drugs that result in significant weight loss. Unfortunately, up to 50% of the total weight loss comes from muscle which is problematic as muscle is necessary for metabolism, strength, and physical function. According to the CDC, 41.5% of older U.S. adults have obesity and could benefit from a weight loss medication. Up to 34.4% of these patients over the age of 60 have sarcopenic obesity which means patients are overweight or obese and also have age-related low muscle mass. Sarcopenic obese patients are potentially at the greatest risk for developing critically low amounts of muscle mass when taking a GLP-1 RA medication for the treatment of obesity. Patients with critically low muscle mass may experience muscle weakness leading to poor balance, decreased gait speed, mobility disability, loss of independence, falls, bone fractures and increased mortality.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VERU:
- Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
- Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs
- Veru to host investor call to discuss financing, enobosarm strategy
- Veru prices 45.8M shares at 72c in underwritten public offering
- Veru $25M Spot Secondary re-offered at 72c